Inorganic Engineered Nanoparticles and Their Impact on the Immune Response

$63.10 plus tax (Refund Policy)

Buy Article:

Abstract:

The immune system is the responsible for body integrity and the prevention of external invasion. In principle, the immune system has not been evolutionarily trained to respond against inorganic engineered nanoparticles (NPs). However, how it will react against them will determine developments on the use of NPs as medical devices and their toxicological impact on human and environmental health. Initial observations show a broad range of results as a function of size, shape, concentration and surface state of NPs, and a variety of immune responses from absent to acute inflammation. In particular for the case of NP, the composition of the material, which strongly influences its physical properties, appears not to be the main determining factor for their behavior in biological environments as compared to surface state or size.





More about this publication?
  • Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more